|
Journal of Aerosol Medicine
Optimum Peripheral Drug Deposition in Patients with Cystic Fibrosis
To cite this article:
P. Brand, T. Meyer, S. Häussermann, M. Schulte, G. Scheuch, T. Bernhard, B. Sommerauer, N. Weber, M. Griese.
Journal of Aerosol Medicine.
Spring 2005,
18(1): 45-54.
doi:10.1089/jam.2005.18.45.
Published in Volume: 18 Issue 1: March 1, 2005
Dr. P. Brand, Ph.D.Inamed–Intelligent Aerosol Medicine GmbH, Gauting, Germany. T. Meyer, M.D.Inamed–Intelligent Aerosol Medicine GmbH, Gauting, Germany. S. Häussermann, Ph.D.Inamed–Intelligent Aerosol Medicine GmbH, Gauting, Germany. M. Schulte, Dipl.Ing.Inamed–Intelligent Aerosol Medicine GmbH, Gauting, Germany. G. Scheuch, Ph.D.Inamed–Intelligent Aerosol Medicine GmbH, Gauting, Germany. T. Bernhard, M.D.Bayer HealthCare LLC, Biological Products, Research Triangle Park, North Carolina. B. Sommerauer, Ph.D.Bayer HealthCare LLC, Biological Products, Research Triangle Park, North Carolina. N. Weber, M.D.Asklepios Fachkliniken, München-Gauting, Germany. M. Griese, M.D.Kinderklinik im Haunerschen Kinderspital, München, Germany. In order to identify the optimum particle size and breathing pattern for high peripheral deposition of inhaled drugs in patients with cystic fibrosis, regional deposition in these patients was studied systematically as a function of particle size, inhalation volume and flow rate. Regional deposition was assessed using the single-breath regional deposition technique in which the concentration profile of inhaled and exhaled non-radioactive, monodisperse test particles is analyzed. Using this technique particle deposition within the functional dead space volume and peripherally can be assessed. Regional deposition was measured in 12 patients with cystic fibrosis using 2, 3, 4, and 5.5 µm particles, inhalation volumes of 500, 1000, 1500, and 2000 cm3, and inhalation flow rates of 100, 250, 500, and 750 cm3/sec. Peripheral deposition was highest when 2–3-µm particles were inhaled with air-flow rates of 250–500 cm3/sec. With these parameters peripheral deposition increased with increasing inhalation volume and reached values of about 60% of the total drug inhaled. It has been shown that high peripheral drug deposition can be achieved in patients with CF when inhalations are performed using an optimized combination of particle size and breathing pattern.  This paper was cited by:Toward Modern Inhalational Bacteriophage Therapy: Nebulization of Bacteriophages of Burkholderia cepacia Complex Laleh Golshahi, Kimberley D. Seed, Jonathan J. Dennis, Warren. H. Finlay Journal of Aerosol Medicine and Pulmonary Drug Delivery. Dec 2008, Vol. 21, No. 4: 351-360 Abstract | Full Text PDF | Reprints & PermissionsIn Vitro Performance Testing of the Novel Medspray® Wet Aerosol Inhaler Based on the Principle of Rayleigh Break-up Anne H. Boer, Jeroen Wissink, Paul Hagedoorn, Iwan Heskamp, Wilbur Kruijf, Ralf Bünder, Pieter Zanen, Paul Munnik, Cees Rijn, Henderik W. Frijlink Pharmaceutical Research. Jun 2008, Vol. 25, No. 5: 1186-1192 CrossRef The science of aerosol delivery in cystic fibrosis David E. Geller Pediatric Pulmonology. Feb 2008: n/a-n/a CrossRef
|
|